Anacardic acid (AnAc; 2-hydroxy-6-alkylbenzoic acid) is a dietary and medicinal phytochemical with established anticancer activity in cell and animal models. The mechanisms by which AnAc inhibits cancer cell proliferation remain undefined. 
Introduction
Anacardic acid (AnAc) is a mixture of 2-hydroxy-6-alkylbenzoic acid homologues that are structurally similar to salicylic acid and aspirin ( Supplementary Fig. S1A ). AnAc is commonly found in plants of the Anacardiaceae family and is a dietary component found in cashew apple (Anacardium occidentale) and ginkgo (Ginkgo biloba) leaves and fruits and is found in several medicinal plants that have potential activity against cancer cell lines (1-4). Oral administration of AnAc to mice had cytotoxic but not genotoxic effects in micronucleus assays of erythrocytes (5) , and AnAc supplied i.p. to mice inhibited the proliferation of implanted Sarcoma 180 ascites cells (6) .
Despite reports showing that AnAc has anticancer activity in cell lines (2, 4, 7) and animal models (6) , its mechanism of action remains largely undefined. AnAc is known to inhibit histone acetyltransferase (HAT; refs. [8] [9] [10] ; thus, the observed antiproliferative activity may be associated with chromatin condensation and altered gene transcription. AnAc also induced apoptosis in chick embryonic neuronal cells; however, no direct molecular mechanism was determined (11) . Thus, AnAc has multiple potential molecular targets that are likely cell type specific as is the case with a variety of natural anticancer phytochemicals such as curcumin (12) .
Because AnAc is reported to have higher efficacy in inhibiting the proliferation of breast cancer cell lines (e.g., MCF-7 and MDA-MB-231) versus cancer cells from other tissues (e.g., lung, liver, bladder, and melanoma; refs. 4, 13), we examined the effect of purified AnAc 24:1 ω5 on the proliferation of estrogen-dependent and estrogen-independent/antiestrogen-resistant breast cancer cells, primary human mammary epithelial cells (HuMEC), and MCF-10A normal breast epithelial cells. Our data indicate that AnAc 24:1 ω5 inhibits the proliferation of estrogen receptor α (ERα)-expressing breast cancer cell lines, irrespective of endocrine sensitivity, with greater efficacy than ERα-negative cells. AnAc 24:1 ω5 does not compete with 17β-estradiol (E 2 ) for ER binding. Rather, AnAc 24:1 ω5 inhibits ER-estrogen response element (ERE) interaction and inhibits the transcription of ER target genes.
Materials and Methods
Chemicals E 2 and 4-hydroxytamoxifen (4-OHT) were purchased from Sigma-Aldrich. AnAc 24:1 ω5 was purified to >95% (Supplementary Fig. S1B and C), as previously reported (14) . Multiple preparations of AnAc 24:1 ω5 were made throughout the course of these studies, and no difference in bioactivities was detected.
Cell Lines
HEK293, MCF-10A, MCF-7, and MDA-MB-231 cell lines were purchased from the American Type Culture Collection and maintained in the recommended medium and supplements. MCF-7-LCC9 (LCC9) and MCF-7-LY2 (LY2) cell lines that express ERα but are estrogen/antiestrogen resistant were provided by Dr. Robert Clarke (Georgetown University, Washington, DC; ref. 15) . Primary HuMECs were purchased from Invitrogen and maintained in HuMEC Ready Medium.
Cell Proliferation Assays
Cells were plated in 96-well plates in normal growth medium and allowed to attach to the plates overnight. Medium was replaced with phenol red-free IMEM supplemented with 3% dextran-coated charcoal-stripped fetal bovine serum (DCC-FBS) for 24 h. AnAc 24:1 ω5 at final concentrations of 1 nmol/L to 100 μmol/L was added for 48 h before doing the bromodeoxyuridine (BrdUrd) ELISA assay (Roche Diagnostics) according to the manufacturer's instructions. Within each experiment, treatments were done in quadruplicate and values were averaged. At least three separate experiments were done for each cell line. IC 50 values were calculated using GraphPad Prism.
Apoptosis Assay
Apoptosis was measured using the Cell Death Detection ELISA PLUS (Roche Diagnostics), which quantitates cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes) after induced cell death, according to the manufacturer's instructions. 4-OHT and doxorubicin served as positive controls for inducing apoptosis in MCF-7 (16) and MDA-MB-231 (17) cells, respectively. Cells (10,000) were plated in 24-well plates, in triplicate wells, using normal growth medium (IMEM containing 5% FBS and penicillin-streptomycin) and allowed to attach for 24 h and then replaced with medium containing charcoal-stripped serum for 24 h followed by treatment with the medium alone (control 1, no treatment), medium containing ethanol (control 2, vehicle control), AnAc 24:1 ω5 (0.1-50 μmol/L), 4-OHT (100 nmol/L), or doxorubicin (1 μmol/L). Whole-cell extracts were prepared after 2 d of treatment.
RNA Isolation, Real-time PCR, and Quantitative Real-time PCR Cells were plated in 24-well plates at a density of 5 × 10 4 per well in phenol red-free Opti-MEM I reduced serum medium (Invitrogen) supplemented with 10% DCC-FBS and 1% penicillin/streptomycin and treated with the indicated concentrations of E 2 and AnAc 24:1 ω5 alone or in combination for 6 h. RNA was isolated from the cells using Trizol (Invitrogen). The High Capacity cDNA Archive kit (PE Applied Biosystems) was used to reverse transcribe total RNA from random hexamer primers. Taqman primers and probes for cyclin D1 (CCND1), TFF1 (pS2), cathepsin D1 (CTSD), and 18S rRNA were purchased as Assays-on-Demand Gene Expression Products from PE Applied Biosystems. The expression of each target gene was determined in triplicate in three separate experiments and normalized using 18S. Quantitative real-time PCR (QRT-PCR) was done in the ABI PRISM 7900 SDS 2.1 (PE Applied Biosystems) using relative quantification. Analysis and fold differences were determined using the comparative C T method. Fold change was calculated from the ΔΔC T values with the formula 2
−ΔΔCT
, and data are presented as relative to expression in ethanol-treated cells (i.e., vehicle control).
Transient Transfection Assays
For transient transfection, HEK293 or MCF-7 cells were plated as described above. Transient transfections were done using FuGENE 6 (Roche Diagnostics). Each well received 250 ng of a pGL3-pro-luciferase reporter (Promega) containing two tandem copies of a consensus ERE (i.e., EREc38; ref. 18 ) and 5 ng of a Renilla luciferase reporter (pRL-TK) from Promega. In addition, HEK293 cells were cotransfected with either pCMV-rhERα or pSG5-rhERβ [provided by Dr. Benita S. Katzenellenbogen (19) (21, 22) was measured by ER adsorption to hydroxyapatite as previously described (21) .
Electrophoretic Mobility Shift Assays
Electrophoretic mobility shift assay (EMSA) experiments were done using baculovirus-expressed rhERα and rhERβ (ERβ1 that was NH 2 -terminal FLAG tagged) and quantified in a Packard Instruments Instant Imager and with Packard Imager for Windows v2.04 as previously described (23 . Antibodies used in the supershift lanes to show the specificity of ER-ERE interaction were G20 (Santa Cruz Biotechnology) and FLAG (Sigma-Aldrich). The IC 50 was determined from the Pseudo-Hill plot: log %/(100 − %) = nlog([I] + nlogIC 50 ), where % = percent competition of specific binding and I = competitor.
ER Protein Stability and Western Blot
The effect of AnAc 24:1 ω5 and ethanol (vehicle control) on steady-state levels of ERα and ERβ was determined by Western blot analysis. MCF-7 cells were seeded into a 10-cm tissue culture dish in phenol red-free IMEM with 10% DCC-FBS. After 24-h incubation, the same medium containing 10 μmol/L AnAc 24:1 ω5 or ethanol was added and cells were harvested after the indicated times. Whole-cell extracts were prepared and equal amounts of protein, as determined in Bio-Rad detergent-compatible protein assay, were separated by 10% SDS-PAGE. Proteins were transferred to polyvinylidene difluoride membranes for Western analysis, and data were quantified as previously described (25) . The following antibodies were used: HC-20 (ERα) and H150 (ERβ) from Santa Cruz Biotechnology, ERβ from Upstate, AER320 (ERα) from Thermo Scientific, and β-actin (for normalization) from Sigma.
Chromatin Immunoprecipitation Assay
MCF-7 cells were transferred to phenol red-free IMEM with 10% DCC-FBS ("starve medium") for 72 h and then treated with 2.5 μmol/L α-amanitin for 2 h. Following three washes in 1× PBS, the cells were treated with ethanol (vehicle), 10 nmol/L E 2 , 10 μmol/L AnAc 24:1 ω5 , or the combination of E 2 and AnAc 24:1 ω5 in "starve" medium for 20 min. Chromatin immunoprecipitation (ChIP) assays were done using the ChIP Assay kit (USB Corp.) according to the instructions supplied. Chromatin was cross-linked using 1.5% formaldehyde for 10 min at 37°C, and the cells were collected after two washings with PBS. Subsequent chromatin fragmentation and preclearing of chromatin suspensions were completed before incubation of the cell extracts with either anti-ERα antibody (HC-20) or normal rabbit IgG (both from Santa Cruz Biotechnology). After elution of the antibody-protein complexes using the kit-supplied reagents, the DNA was purified using the PCR Cleanup kit (Qiagen).
QRT-PCR with ChIP Samples
QRT-PCR was done using 3 μL of the purified, immunoprecipitated DNA and probed for pS2 [trefoil factor 1 (TFF1)] using primers flanking the established ERE in the human pS2 gene promoter (26) and SYBR Green Master Mix (SABiosciences). The data were calculated as described by Aparicio et al. (27) . The average C T values of the input samples (before immunoprecipitation) were subtracted from the average C T values for the ERα antibody immunoprecipitated value to obtain the net C T value, which was subtracted from the control (IgG) C T value. Relative promoter enrichment was compared with IgG (28), and expression of the pS2 gene was expressed relative to ethanol. The pS2 PCR products in representative wells from each treatment group were separated on a 1.5% agarose gel for visualization of the amplified products. A 1-kb DNA ladder (Promega) was run in parallel with the samples.
Statistical Analyses
Student's t test or one-way ANOVA followed by Dunn's multiple comparison or Dunnett's post hoc test was done with GraphPad Prism.
Molecular Modeling
Surflex 2.3 docking module (Surflex-dock) running under Sybyl 8.1 was used to determine the interaction potential of AnAc 24:1 ω5 and several other small reference molecules to the ligand binding domain (LBD) and DNA binding domains (DBD) of ERα. Surflex-dock GeomX parameters were selected. Protein Data Bank (PDB) structure 1ERE (29) was used as a representative ERα LBD structure, and 1HCQ (30) was used for the ERα DBD structure. Note that the crystal structure of the ERα DBD is bound as a homodimer to a consensus ERE palindrome. The ligand binding site for the LBD structure of ERα was determined by Surflex-dock protomol generation in "ligand mode" with "1ERE A-chain" (the ERα LBD) and E 2 . The potential ligand interaction site for the ERα DBD was determined by Surflex-dock protomol generation in "automatic mode" (i.e., the ERα DBD was not cocrystallized with a ligand) using ERα DBD (1HCQ) A and B chains with associated zinc atoms. Sybyl's Biopolymer Structure Preparation Tool was used to prepare both PDB files for virtual docking. AnAc 24:1 ω5 (2-hydroxy-6-alkylbenzoic acid), aspirin (acetylsalicylic acid), salicylic acid, E 2 , and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) used for docking were initially minimized and charged using Sybyl 8.1 MMFF94 force field.
Surflex-dock returns an affinity score reported as −log(Kd) that takes into account hydrophobic, polar complimentarity, entropic, and solvation terms (31) and a "crash" score that represents "inappropriate" penetration of a potential ligand into a binding site (32) . For these analyses, crash scores >2 units (indicating an unfavorable protein-ligand interaction) were used to reject compound interaction even with high estimated affinity scores to limit false-positive predictions of protein-ligand interactions.
Results

AnAc Inhibits Normal or Breast Cancer Cell Proliferation in Accordance with ERα Status
The effect of AnAc 24:1 ω5 on the proliferation of primary HuMECs, one normal breast epithelial, and four breast cancer cell lines differing in their ER status and/ or sensitivity to the antiestrogens tamoxifen and ICI 182,780 (15) was evaluated by BrdUrd incorporation ( Fig. 1; Supplementary Figs. S2 and S3 ). MCF-7 cells responded proliferatively to E 2 , whereas all other cell lines were non E 2 -responsive, regardless of ER status, consistent with previously published reports (25, 33) . As expected, MCF-10A cells and the tamoxifen-resistant LCC9 and LY2 cells showed no inhibition by 4-OHT, whereas E 2 -induced proliferation in MCF-7 cells was significantly reduced by 4-OHT. AnAc 24:1 ω5 dose-response curves ( Supplementary Fig. S3 ) indicated that ERα-positive cell lines are inhibited to a greater extent with IC 50 values of ∼2-to 6.6-fold lower than cell lines that are ERα negative. In all cell lines, 50 μmol/L AnAc 24:1 ω5 was more effective at inhibiting BrdUrd incorporation than 100 nmol/L 4-OHT, regardless of tamoxifen sensitivity (Fig. 1) , and inhibition by 50 μmol/L AnAc 24:1 ω5 was not reversed by E 2 or 4-OHT. Importantly, AnAc 24:1 ω5 did not inhibit the proliferation of ERα-negative (34) primary HuMECs ( Supplementary Fig. S2 ).
AnAc Stimulates Apoptosis in Breast Cancer Cell Lines
To determine the phase of the cell cycle at which AnAc 24:1 ω5 exerts its growth-inhibitory effect, MCF-7, LY2, and MCF-10A cells were subjected to fluorescence-activated cell sorting (FACS) analysis ( Fig. 2A ). AnAc 24:1 ω5 inhibited cell cycle progression from the G 1 phase of the cell cycle in MCF-7 and LY2 cancer cell lines but not in normal MCF-10A cells. Approximately 80% of MCF-7 and LY2 cells were in the G 1 phase after 24 hours of AnAc 24:1 ω5 treatment in comparison with only 60% of control cells observed to be in G 1 after 24 hours (Fig. 2A) .
Because AnAc 24:1 ω5 resulted in more growth inhibition in MCF-7 than MDA-MB-231 cells, we examined the relative induction of apoptosis in these two cell lines using 4-OHT and doxorubicin as positive controls, respectively. AnAc 24:1 ω5 induced a concentration-dependent increase in apoptosis in both cell lines with a greater effect on MCF-7 cells (Fig. 2B) , results in concordance with the greater inhibition of cell proliferation in MCF-7 cells (Supplementary Fig. S3 ).
AnAc Inhibits ER-Induced Gene Transcription
Because AnAc 24:1 ω5 showed greater efficacy in inhibiting the proliferation of ERα-expressing breast cancer cells ( Fig. 1; Supplementary Figs. S2 and S3 ), the effect of AnAc 24:1 ω5 on the transcription of established endogenous E 2 , alone or in combination, as indicated, for 48 h before examining BrdUrd incorporation as described in Materials and Methods. Values are the mean ± SEM of three to five independent experiments, in which each treatment within that experiment was done in quadruplicate. a, P < 0.05, treatments that were significantly different from ethanol (EtOH) control; b, P < 0.05, treatments in combination with E 2 that were significantly different from E 2 alone.
target genes CCND1 (regulates G 1 cell cycle progression), CTSD (a lysosomal protease involved in breast cancer metastases), and pS2 (TFF1; a well-established E 2 -responsive breast cancer marker gene of unknown function; ref. 35) was evaluated by QRT-PCR (Fig. 3A-C) . CCND1 was increased ∼3.5-fold in E 2 -treated MCF-7 cells but was unaffected by E 2 in LCC9 or LY2 cells, in agreement with the endocrine-resistant status of these ERα-positive cells (25) . In contrast, 20 μmol/L AnAc 24:1 ω5 reduced CCND1
to below basal levels in MCF-7 and LCC9 cells, whereas CCND1 in LY2 cells was slightly, but statistically significantly, increased. Cotreatment with E 2 and 40 μmol/L AnAc 24:1 ω5 reduced CCND1 transcript levels to or below basal in all ERα-positive cell lines. As anticipated, E 2 did not increase CCND1 levels in ERα-negative MCF-10A or MDA-MB-231 cell lines. AnAc 24:1 ω5 , individually or in combination with E 2 , reduced CCND1 to below basal in MCF-10A or MDA-MB-231 cells (Fig. 3A) . , and TFF1 (pS2; C) were analyzed by real-time QRT-PCR as described in Materials and Methods. For MCF-10A and MDA-MB-231, CCND1 basal expression was ∼25-and 114-fold higher than MCF-7 cells, respectively. For LY2, MCF-10A, and MDA-MB-231, CTSD basal expression was ∼2-, 172-, and 138-fold higher than MCF-7 cells, respectively. C, no TFF1 expression was detected in cell lines other than MCF-7. The effect of AnAc 24:1 ω5 on each ER subtype (D) was examined in HEK293 cells that were cotransfected with ERα (top) or ERβ (middle), in addition to an ERE-luciferase reporter and pRL-TK as described in Materials and Methods. MCF-7 cells (bottom) were transfected with the same ERE-luciferase reporter and pRL-TK as described in Materials and Methods. Twenty-four hours after transfection, the cells were treated with ethanol (ethanol), 10 nmol/L E 2 , or the indicated concentrations of AnAc 24:1 ω5 alone (solid lines, open squares) or in combination with 10 nmol/L E 2 (dashed lines, filled circles). Dual luciferase activity was assayed as described in Materials and Methods. Data are displayed as relative luciferase activity (fold difference) in which the ethanol activity was set to 1. For all panels, data are the mean ± SEM from three separate experiments. a, P < 0.05, significantly different from ethanol control; b, P < 0.05, values from combined treatments that were significantly different compared with E 2 alone.
CTSD expression in LCC9 cells (Fig. 3B ). As anticipated, E 2 did not increase CTSD levels in ERα-negative MCF-10A or MDA-MB-231 cell lines. AnAc 24:1 ω5 , alone or in combination with E 2 , reduced CTSD below basal levels in MCF-10A and MDA-MB-231 cells (Fig. 3B) .
Transcript levels of pS2 (TFF1) were increased by E 2 in MCF-7 cells, whereas 20 μmol/L AnAc 24:1 ω5 reduced transcript levels to below basal (0.2-fold; Fig. 3C ). As anticipated, based on the tamoxifen/endocrine resistance of these cells (25), TFF1 was not detected in LCC9 or LY2 cells (data not shown). The TFF1 expression pattern in MCF-7 cells treated simultaneously with 10 nmol/L E 2 and AnAc 24:1 ω5 (10, 20, and 40 μmol/L) largely mirrored the pattern observed for CCND1 expression with a concentration-dependent inhibition of E 2 -dependent transcription (Fig. 3C) .
AnAc Inhibits ERα-and ERβ-ERE Reporter Gene Transcription
To directly assess the effect of AnAc 24:1 ω5 on the transcriptional activity of each ER subtype (ERα or ERβ), HEK293 cells were transfected with either ERα or ERβ expression plasmids and an ERE-driven luciferase reporter (Fig. 3D ). As expected, E 2 increased luciferase activity for both ERα and ERβ. AnAc 24:1 ω 5 (alone) did not produce a clear concentration-dependent response in ER-transfected HEK293 cells; however, a modest, but significant, agonist activity was apparent at some concentrations, although most concentrations tested were not significantly different from control. Treatment of HEK293-ERα with E 2 in combination with lower concentrations of AnAc 24:1 ω5 (1 and 10 μmol/L) showed no significant difference relative to E 2 alone. However, ≥25 μmol/L AnAc 24:1 ω5 inhibited E 2 -induced reporter activity. Similar results were seen for HEK293-ERβ, except that 50 and 75 μmol/L AnAc 24:1 ω5 reduced luciferase below basal (Fig. 3D) . These data indicate that AnAc 24:1 ω5 inhibited E 2 -mediated ERα and ERβ transcriptional activity. For comparison, the effect of AnAc 24:1 ω5 on endogenous ER activity was examined in MCF-7 cells transiently transfected with the same ERE-luciferase reporter (Fig. 3D) . At the lowest concentrations tested (0.1-10 μmol/L), AnAc 24:1 ω5 alone had no effect on luciferase activity, but at 25 and 50 μmol/L, luciferase activity was completely inhibited. Cotreatment of MCF-7 cells with 10 nmol/L E 2 and AnAc 24:1 ω5 resulted in a concentration-dependent inhibition of E 2 -mediated reporter activity. These data indicate a greater sensitivity of MCF-7 cells to AnAc 24:1 ω5 inhibition of E 2 -induced ERE-driven reporter activity compared with HEK293 transfected with ERα or ERβ. Further, these data correlate with the inhibition of endogenous E 2 -activated gene transcription in MCF-7 cells (Fig. 3A-C ). AnAc 24:1 ω5 was more efficacious in inhibiting the ERE-luciferase activity compared with endogenous gene transcription (Fig. 3) , likely reflecting the lack of mature chromatin structure on the transfected ERE-luciferase plasmid or other factors such as differences in molar ratio of ER and AnAc 24:1 ω5 in each assay. (Fig. 4A and B) , indicating that AnAc 24:1 ω5 does not interact directly with the ligand binding pocket of either ER subtype.
The effect of AnAc 24:1 ω5 on ER binding to a consensus ERE sequence was examined by EMSA ( Fig. 4C  and D; Supplementary Fig. S4 ). The ERE binding of both ER subtypes was inhibited by AnAc 24:1 ω5 in a concentration-dependent manner. Salicylic acid did not inhibit ER-ERE binding (Supplementary Fig. S4C 
-ERα Interaction with the pS2 Gene Promoter in MCF-7 Cells
Because AnAc 24:1 ω5 inhibited transcription of E 2 -dependent genes and ER/ERE interactions (Fig. 3) , ChIP assays were used to evaluate whether AnAc 24:1 ω5 inhibits E 2 -induced ERα interaction with the ERE-containing, E 2 -regulated, human pS2 (TFF1; ref. 36 ) gene promoter in vivo. ERα-specific antibody or IgG (negative control) was used to immunoprecipitate protein-DNA complexes from whole-cell extracts of MCF-7 cells treated with ethanol, 10 nmol/L E 2 , 10 μmol/L AnAc 24:1 ω5 , or both E 2 and AnAc 24:1 ω5 . QRT-PCR was done on the ChIP samples to examine the enrichment of the pS2 promoter by ERα. In agreement with previous reports, QRT-PCR showed that E 2 induced ERα occupancy of the pS2 promoter (Fig. 5A) . As anticipated based on gene transcription data (Fig. 3C) , cotreatment of MCF-7 cells with E 2 and AnAc 24:1 ω5 blocked E 2 -induced ERα recruitment ( Fig. 5A and B) . We conclude that AnAc 24:1 ω5 inhibits E 2 -ERα-DNA interaction on the pS2 promoter in MCF-7 cells.
AnAc Does Not Reduce Steady-State Protein Levels of ERα or ERβ
ERα ligands affect ERα protein stability (37, 38 ). An alternative explanation for the observed reduction in E 2 -activated gene transcription by AnAc 24:1 ω5 could be reduced ER protein levels. The effect of 10 μmol/L AnAc 24:1 ω5 steady-state protein levels of ERα and ERβ was evaluated by Western blotting with two different antibodies for each ER subtype (Fig. 5C and D) . There was no statistical difference in ERα or ERβ protein expression over the 12-hour time course that was selected to parallel gene transcription (Fig. 3) and ChIP ( Fig. 5A and B) studies. These data indicate that AnAc 24:1 ω5 does not cause a rapid reduction in ER protein.
Molecular Modeling of AnAc 24:1 ω5 Interaction with ERα
Molecular modeling approaches were used to assess the potential interactions of ERα with AnAc 24:1 ω5 and structurally similar molecules (aspirin and salicylic acid; Supplementary Fig. S1 ), as well as with known positive and negative controls for the LBD and/or the DBD of ERα. To validate that Surflex will detect high-affinity E 2 -ERα LBD interaction, Surflex-docking experiments were done and the natural ligand E 2 was successfully docked to the ERα LBD with an affinity score of 7.17 and a crash score of only −0.79. Aspirin and salicylic acid were estimated to bind to the ERα LBD with apparent lower affinities of 4.45 and 3.59, respectively (with crash scores of −1.20 and −0.32). TCDD functioned as our negative control because it is not known to bind ERα (39) . TCDD was estimated to have a score of −0.03 and a crash score of −1.86 (i.e., no affinity) for the ERα LBD. AnAc 24:1 ω5 was estimated to have a 9.05 affinity score for the ERα LBD. However, the accompanying crash score of −5.36 indicates a high degree of inappropriate ligand-protein interactions and thus allows the conclusion that (Fig. 4A) .
When modeling the ERα DBD as a potential target for small-molecule interactions, aspirin and salicylic acid had low affinity (3.91 and 4.05, with crash scores of −0.48 and −0.34, respectively) for the ERα DBD and TCDD again had almost no affinity (value of only 1.31 with crash score of −0.33). Remarkably, AnAc 24:1 ω5 was found to have an affinity value of 8.01 units and a crash score of only −1.28 for the ERα DBD, indicating that AnAc 24:1 ω5 may interact directly with the DBD and thus interfere with the ability of the ER to interact with an ERE. Visualization of AnAc 24:1 ω5 docked to the ERα DBD reveals that the compound lies between the zinc fingers ( Fig. 6A) and traverses from one side of the protein to the other (Fig. 6B) . Because the structurally similar aspirin and salicylic acid did not yield comparable modeling results, it seems that the alkyl chain of AnAc 24:1 ω5 may be an important factor, in combination with the salicylic ring structure, for ERα DBD interaction. More complete structure-activity relationship studies are needed to fully address this suggestion.
Discussion
Tamoxifen/endocrine resistance is a major problem in the treatment of breast cancer patients (40) ω5 with another site on ER that modulates E 2 activation (e.g., the DBD). This assertion is supported by the virtual molecular docking experiments wherein AnAc 24:1 ω5 was estimated to have a relatively high affinity for the ERα DBD and no affinity for the ERα LBD. The computational modeling is supported by in vitro EMSA data confirming DBD interference ( Fig. 4C and D) , the lack of LBD interaction detected in the E 2 binding competition assays ( Fig. 4A and B) , and the ChIP data showing that treatment of MCF-7 cells with AnAc 24:1 ω5 blocked E 2 -induced ERα occupancy of the endogenous pS2 gene promoter in MCF-7 cells. Together, based on our in vitro, ChIP, and in silico experimental data, we suggest that the molecular mechanism by which AnAc 24:1 ω5 preferentially inhibits the cell proliferation of ERα-positive breast cancer cell lines is by interfering with ER-DNA interactions.
The fact that AnAc 24:1 ω5 inhibited ERα-negative MDA-MB-231 and MCF-10A cell proliferation, although with reduced efficacy, also indicates that AnAc 24:1 ω5 acts through ERα-independent mechanisms. Both MDA-MB-231 and MCF-10A express ERβ (42) , and given the high homology between the DBDs of ERα and ERβ (43) , it is possible that AnAc would also interact with the ERβ DBD. Because the crystal structure of the ERβ DBD has not been examined, this possibility cannot be tested in Surflex. Alternatively, AnAc has been reported to inhibit HAT activity in vitro (8-10). Many transcription factors, including ER, recruit coactivators with HAT activity to initiate gene transcription (44) . Thus, inhibition of HAT activity by AnAc may reduce the expression of genes required for cell proliferation. Interestingly, a series of substituted phenoxyacetic acid ethyl esters, structurally related to AnAc, were shown to inhibit MCF-7 cell proliferation and this was correlated with HAT inhibition in vitro (45) . Thus, the potential inhibition of HAT activity by AnAc 24:1 ω5 would fit the inhibition of basal CCND1 expression that we observed (Fig. 3A) .
AnAc 24:1 ω5 inhibited E 2 -induced endogenous CCND1 transcription in MCF-7 cells. CCND1 is a well-established ERα genomic target (46) involved in cell cycle progression (47). Based on our EMSA and molecular modeling data, we suggest that the inhibition of E 2 -induced CCND1 transcription by AnAc 24:1 ω5 may result from the direct interaction of AnAc 24:1 ω5 with the DBD of ERα that could prevent ERα interaction with a 3′ flanking region (46) . However, because E 2 -ERα regulates CCND1 transcription via multiple mechanisms including tethering of ERα with AP-1 (48), the precise mechanism of inhibition remains to be established. Likewise, the inhibition of E 2 -induced endogenous CTSD transcription in MCF-7 and LCC9 cells may not be due to blocking direct ER-DNA interaction because transcription is mediated by ERα-Sp1 interaction at GC boxes in the CTSD promoter (49) . It is possible that AnAc 24:1 ω5 interaction with the DBD could affect ERα-Sp1 interaction because deletion studies indicated the importance of the ERα DBD for ligand-activated Sp1 interaction (50) . Notably, AnAc 24:1 ω5 suppressed basal CTSD transcription in LY2 cells, a promising result given the greater endocrine resistance in LY2 cells compared with LCC9 cells (25) . The apparent biphasic effect of AnAc 24:1 ω5 in the ERE-luciferase assay in ER-transfected HEK293 cells is similar to that for other natural ER inhibitors (e.g., apigenin), although apigenin acts by a different mechanism than AnAc 24:1 ω5 (i.e., apigenin induces ERα degradation; ref. 37) , which AnAc 24:1 ω5 does not. In conclusion, our data provide a mechanism to account for the observation that breast cancer cells expressing ERα are more than twice as sensitive to inhibition by AnAc 24:1 ω5 regardless of their endocrine/tamoxifen sensitivity. AnAc 24:1 ω5 may preferentially inhibit ERα-positive breast cancer cell proliferation by direct ER DBD interaction. The fact that AnAc 24:1 ω5 inhibits the proliferation of estrogen-dependent and estrogen-independent breast cancer cells, but not primary HuMECs, is an indication that the distinct mode(s) of AnAc 24:1 ω5 -mediated inhibition might be further therapeutically exploited.
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